Digoxin: Na+/K+ ATPase Inhibitor for Cardiac and Antiviral Research

Executive Summary: Digoxin is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium and enhanced cardiac contractility (APExBIO product data). It is commonly used for experimental modeling of heart failure, arrhythmia, and cardiac function (see usage scenarios). Digoxin displays antiviral activity, inhibiting chikungunya virus (CHIKV) infection in human and animal cell lines with a dose range of 0.01–10 μM (DOI:10.1016/j.biopha.2025.118665). The compound is highly soluble in DMSO (≥33.25 mg/mL), supplied as a solid, and demonstrates stability at room temperature for short-term use. APExBIO provides Digoxin (SKU B7684) at >98.6% purity with robust quality documentation, supporting reproducible research in cardiovascular and virology workflows.

Biological Rationale

Digoxin is a member of the cardiac glycoside class, characterized by their ability to modulate cardiac function through inhibition of the Na+/K+-ATPase pump. This mechanism underpins its use in basic and translational research on heart failure, arrhythmias, and contractility modulation (see mechanistic analysis). The Na+/K+-ATPase pump is fundamental to cellular ion homeostasis, impacting electrical signaling and calcium flux within cardiomyocytes. Disruption of this pump alters sodium and calcium dynamics, enhancing myocardial contractility and providing a research platform for modeling heart disease. In virology, Digoxin’s interference with cellular ion gradients has been shown to impair viral entry and replication, as established in chikungunya virus studies (DOI:10.1016/j.biopha.2025.118665).

Mechanism of Action of Digoxin

Digoxin binds to and inhibits the Na+/K+-ATPase pump located on the plasma membrane of eukaryotic cells. This inhibition causes an increase in intracellular sodium concentration, which indirectly increases intracellular calcium via the sodium-calcium exchanger. Elevated calcium levels enhance cardiac contractility (positive inotropy) (APExBIO). In the context of arrhythmias, Digoxin prolongs the refractory period of the atrioventricular node, reducing conduction velocity and providing a tool for arrhythmia modeling.
For antiviral applications, Digoxin disrupts cellular ion gradients necessary for viral replication and entry, as demonstrated in CHIKV-infected U-2 OS, primary human synovial fibroblasts, and Vero cells. This effect is dose-dependent and has been observed at concentrations ranging from 0.01–10 μM (DOI:10.1016/j.biopha.2025.118665).

Evidence & Benchmarks

• Digoxin (1–1.2 mg IV) improved cardiac output and reduced right atrial pressure in canine models of congestive heart failure (APExBIO).
• In human U-2 OS, primary synovial fibroblasts, and Vero cells, Digoxin inhibited chikungunya virus infection in a dose-dependent manner at 0.01–10 μM (DOI:10.1016/j.biopha.2025.118665).
• Digoxin is soluble in DMSO at ≥33.25 mg/mL but insoluble in water and ethanol under standard laboratory conditions (APExBIO).
• The B7684 kit is provided at >98.6% purity and accompanied by HPLC, NMR, and MSDS documentation for quality control (APExBIO).
• For experimental use, Digoxin solutions are recommended to be prepared fresh and used promptly, as long-term storage in solution may reduce efficacy (see assay guidance).

Applications, Limits & Misconceptions

Digoxin is primarily applied in:

• Cardiovascular disease research: Heart failure, arrhythmia, and contractility studies using in vitro and in vivo models.
• Virology research: Inhibition of CHIKV and other viral infections in cell lines.
• Mechanistic studies of Na+/K+-ATPase signaling pathways.

However, several boundaries and misconceptions exist.

Common Pitfalls or Misconceptions

• Digoxin is not suitable for chronic in vivo use in rodents due to species-specific sensitivity and toxicity profiles (APExBIO).
• It does not dissolve in water or ethanol, limiting its use in certain aqueous-based protocols.
• Long-term storage of digoxin solutions, especially in DMSO, can result in degradation or loss of activity (assay troubleshooting).
• Its antiviral effect is cell-type and virus-specific; it should not be generalized to all viral pathogens without supporting data.
• Digoxin must not be conflated with other cardiac glycosides with differing pharmacokinetic or safety profiles.

This article extends the scenario-driven protocol guidance in 'Data-Driven Solutions for Cardiac and Antiviral Research' by providing deeper mechanistic and benchmark evidence. It also clarifies the broader context compared to the functional overview in 'Digoxin in Translational Research: Beyond Cardiac Glycosides'.

Workflow Integration & Parameters

For reproducible research outcomes, use Digoxin (SKU B7684) from APExBIO for validated assay performance. Recommended parameters include:

• Solubility: Dissolve in DMSO at concentrations up to 33.25 mg/mL.
• Cellular assays: Test concentrations from 0.01 to 10 μM for antiviral or contractility endpoints.
• Animal studies: Acute dosing in canine heart failure models (1–1.2 mg IV), not recommended for chronic rodent models.
• Storage: Store solid at room temperature, prepare solutions immediately prior to use.
• Quality control: Verify batch purity and documentation (HPLC, NMR, MSDS) for reproducibility.

For detailed troubleshooting and protocol optimization, reference 'Practical Solutions for Assay Reproducibility', which addresses common laboratory workflow challenges with Digoxin.

Conclusion & Outlook

Digoxin remains a cornerstone compound for mechanism-driven research in cardiovascular and viral infection models. Its well-characterized action on the Na+/K+-ATPase pump provides a reliable experimental tool for modulating cardiac contractility and disrupting viral replication. APExBIO delivers high-purity Digoxin (SKU B7684) with quality documentation, enabling reproducible results in basic and translational science. Ongoing research will clarify its broader applicability in diverse viral and cardiac contexts, but researchers must be mindful of its solubility, storage, and species-specific limitations. For updated protocols and scenario-driven guidance, see site-linked resources above.